Astellas Pharma Delivers Strong FY2025 Financial Results
Astellas Pharma Inc. unveiled impressive full-year fiscal 2025 results during its latest earnings call, marking record revenue and significant profit growth. The company achieved revenue of 2,139.2 billion yen, a 11.9% increase year-over-year, surpassing 2 trillion yen for the first time and securing double-digit growth for the second straight year.
Core operating profit reached 555.7 billion yen, up 41.6% from the prior year, with the margin expanding to 26%, an improvement of 5.5 percentage points. Net profit stood at 291.6 billion yen, reflecting substantial gains, while full operating profit rose to 382.6 billion yen.
Key Drivers: Strategic Brands Surge
Strategic brands fueled the performance, posting combined sales of 480 billion yen, a 43% jump or 143.9 billion yen increase year-over-year. Standout performers included:
- PADCEV: 221.2 billion yen, up 35%, boosted by first-line muscle-invasive bladder cancer penetration and new indications.
- XOSPATA: 77.6 billion yen, up 33%, with rising new patient starts.
- VYLOY: 63.1 billion yen, exceeding expectations due to strong testing rates.
- XTANDI: 960.8 billion yen, up 5%, hitting projected peak sales 13 years after launch.
Cost optimization efforts under the SMT initiative saved approximately 25 billion yen across SG&A, R&D, and cost of sales, improving the SG&A ratio by 2.3 percentage points.
Pipeline Advances and FY2026 Guidance
Executives highlighted pipeline progress, including three Proof-of-Concept achievements and Phase III initiations for key candidates like ASP2138 and others. New licenses and clinical entries signal ongoing innovation.
For fiscal 2026, Astellas forecasts revenue above 2,200 billion yen, up about 3.5%, with core operating profit exceeding 600 billion yen, up 12%, and a margin of 27.9%. Strategic brands are projected to grow by over 130 billion yen to around 610 billion yen. R&D expenses will rise to 355 billion yen, offset by 40 billion yen in SMT savings. Dividend increases to 80 yen per share.
CEO Naoki Okamura emphasized, “Our record-breaking results reflect commitment to innovation and strategic growth, while staying vigilant on challenges like XTANDI declines from pricing and patents.”
Insights from Q&A Session
Analysts probed XTANDI’s Q4 softness, attributed to U.S. market dynamics and upcoming IRA impacts. PADCEV’s momentum continues with pending approvals. On M&A, Okamura clarified, “We have no intention to pursue large deals to offset dips; focus remains on internal pipeline.”
CFO Atsushi Kitamura noted sustainable dividend plans based on cash flow. The company anticipates XTANDI sales to drop around 50 billion yen due to external pressures but prioritizes portfolio diversification and efficiency.
